Latest News

Aug 2024

What Happens Now That The FDA Rejected Ecstasy-Assisted Therapy For PTSD? Experts Weigh In

Nov 2023

What If Psychedelics’ Hallucinations Are Just a Side Effect?

July 2023

Recognizing Inspiring Achievements From 2023

Sep 2022

Taking The Tripping Out Of Psychedelic Medicine

Sep 2022

Ketamine, Psilocybin And Ecstasy Are Coming To The Medicine Cabinet

Dec 2024

Delix Presents Full Results from Phase 1 Trial of DLX-001 at ACNP Annual Meeting

Dec 2024

Delix Therapeutics Announces Dosing of First Patient in Phase 1b Clinical Trial for DLX-001 in Major Depressive Disorder

July 2024

Delix Plans Further Trials With Neuroplastogen After Positive Phase I Data

June 2024

Delix Therapeutics Awarded Grant from the U.S. Department of Defense to Advance Neuroplastogen for Hearing Loss

May 2024

Delix Announces DLX-001 Demonstrates Evidence of CNS Penetration and Brain Activity Without Psychotomimetic, Dissociative, or Hallucinogenic Effects in Ongoing Phase 1 Trial

Dec 2023

Delix Therapeutics Awarded National Institutes of Health Grant to Advance Vital Research of Novel Neuroplastogen for Substance Use Disorders

Dec 2023

Delix Therapeutics Awarded National Institutes of Health Grant to Advance Vital Research of Novel Neuroplastogen for Substance Use Disorders

Dec 2023

Delix Presents Interim Data From Phase I Trial of Novel Neuroplastogen at ACNP Annual Meeting

July 2023

The Galien Foundation Announces 2023 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup"

June 2023

Delix Therapeutics Announces Completion of 1st Cohort Dosing, Dose Escalation Approval in Phase I Trial for Novel Compound DLX-001

May 2023

Delix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001

June 2023

Delix Therapeutics Appoints Aaron Koenig, MD as Chief Medical Officer

Feb 2023

Pioneering Delix Therapeutics Study Published in 'Science' Elucidates the Mechanism of Psychedelic-Induced Neuroplasticity

Feb 2023

Delix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and Translatability

Sept 2022

Nature Biotechnology’s academic spinouts 2021

Sept 2022

Nature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-Up

Sept 2022

Delix Therapeutics Expands World-Class Team with First Head of R&D

Sept 2022

Delix Therapeutics and Pfizer UK Recognized as Gender Equity Champions for Women in the Workplace by Healthcare Businesswomen's Association

Aug 2022

Get Ready for the Magic Mushroom Pill

July 2022

Accessibility Is Key for the Psychedelic Revolution

July 2022

Taking the Magic Out of Magic Mushrooms

Mar 2022

Drug Companies Are Investing Big In Psychedelics, But Can They Engineer Out The Trip?

Jan 2022

Delix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million Strategic Credit Facility Option in Partnership with Comerica Bank

Jan 2022

The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of